Filing Flows › Adma Biologics (ADMA) › Q3 2026 › vs Q2 2026
Adma Biologics (ADMA) Q3 2026 vs Q2 2026 (quarter over quarter)
Adma Biologics's revenue rose $16.7M (+13%) from $124M in Q2 2026 to $141M in Q3 2026. Gross margin 70.8% against 69.4% (+1.5 pts).
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.8% | 69.4% | +1.5 pts |
| Operating margin | 48.0% | 42.2% | +5.9 pts |
| Net margin | 35.4% | 30.4% | +4.9 pts |
| Free cash flow margin | 10.9% | 21.9% | -11.0 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $141M | $124M | $16.7M | +13% |
| Gross profit | $99.9M | $86.3M | $13.6M | +16% |
| Cost of revenue | $41.2M | $38.1M | $3.1M | +8% |
| Operating profit | $67.8M | $52.4M | $15.3M | +29% |
| Operating expenses | $32.2M | $33.8M | −$1.7M | -5% |
| Pre-tax earnings | $65.6M | $50.2M | $15.4M | +31% |
| Other expense, net | $2.2M | $2.2M | −$55K | -2% |
| Research & development | $4.5M | $6.0M | −$1.5M | -25% |
| SG&A | $26.6M | $26.7M | −$182K | -0.7% |
| Other operating costs | $1.1M | $1.1M | $34K | +3% |
| Net earnings | $49.9M | $37.8M | $12.1M | +32% |
| Income tax | $15.7M | $12.4M | $3.3M | +27% |
| Depreciation & amortization | $1.7M | $1.7M | $0 | 0% |
| Share-based compensation | $6.2M | $6.1M | $68K | +1% |
| Working capital & other | $40.4M | $16.1M | $24.3M | +151% |
| Operating cash flow | $17.4M | $29.5M | −$12.2M | -41% |
| Free cash flow (OCF − capex) | $15.4M | $27.3M | −$11.9M | -44% |
| Capital expenditures | $2.0M | $2.3M | −$254K | -11% |
Questions
How much did Adma Biologics's revenue grow quarter over quarter in Q3 2026?
Adma Biologics's revenue rose $16.7M (+13%) from $124M in Q2 2026 to $141M in Q3 2026. Gross margin 70.8% against 69.4% (+1.5 pts).